Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.24
MRNA's Cash-to-Debt is ranked lower than
92% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. MRNA: 0.24 )
Ranked among companies with meaningful Cash-to-Debt only.
MRNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 10.52 Max: No Debt
Current: 0.24
Equity-to-Asset 0.52
MRNA's Equity-to-Asset is ranked lower than
87% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MRNA: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
MRNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -2  Med: 0.67 Max: 0.95
Current: 0.52
-2
0.95
Piotroski F-Score: 2
Altman Z-Score: 3.98
Beneish M-Score: -3.35
WACC vs ROIC
21.58%
-30.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 289.60
MRNA's Operating Margin % is ranked lower than
71% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. MRNA: 289.60 )
Ranked among companies with meaningful Operating Margin % only.
MRNA' s Operating Margin % Range Over the Past 10 Years
Min: -2259.18  Med: -502.33 Max: 289.6
Current: 289.6
-2259.18
289.6
Net Margin % 1194.80
MRNA's Net Margin % is ranked higher than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. MRNA: 1194.80 )
Ranked among companies with meaningful Net Margin % only.
MRNA' s Net Margin % Range Over the Past 10 Years
Min: -2269.84  Med: -708.47 Max: 1194.8
Current: 1194.8
-2269.84
1194.8
ROE % -140.87
MRNA's ROE % is ranked higher than
100% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. MRNA: -140.87 )
Ranked among companies with meaningful ROE % only.
MRNA' s ROE % Range Over the Past 10 Years
Min: -539.78  Med: -329.36 Max: -50.59
Current: -140.87
-539.78
-50.59
ROA % -44.57
MRNA's ROA % is ranked higher than
92% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. MRNA: -44.57 )
Ranked among companies with meaningful ROA % only.
MRNA' s ROA % Range Over the Past 10 Years
Min: -158.44  Med: -78.17 Max: -20.68
Current: -44.57
-158.44
-20.68
3-Year Revenue Growth Rate -100.00
MRNA's 3-Year Revenue Growth Rate is ranked lower than
86% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. MRNA: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MRNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -28.55 Max: 72
Current: -100
-100
72
3-Year EBITDA Growth Rate -40.30
MRNA's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MRNA: -40.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MRNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.1 Max: 108.5
Current: -40.3
0
108.5
3-Year EPS without NRI Growth Rate -39.40
MRNA's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MRNA: -39.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MRNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.1  Med: -10.25 Max: 102.4
Current: -39.4
-82.1
102.4
GuruFocus has detected 2 Warning Signs with Marina Biotech Inc $MRNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MRNA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:RGRX, OTCPK:IPATF, NAS:XBIO, NAS:MIRN, AMEX:CANF, NAS:VKTX, NAS:ICCC, NAS:OCRX, NAS:CATB, NAS:ADHD, NAS:DMPI, NAS:TPIV, OTCPK:CVALF, OTCPK:GBLX, NAS:EARS, NAS:DFFN, OTCPK:PXRB, AMEX:IBIO, NAS:CSBR, NAS:PTIE » details
Headquarter Location:USA
Marina Biotech Inc is a biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs.

Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

Top Ranked Articles about Marina Biotech Inc

Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French

BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J. Michael French, chairman of the board, president and chief executive officer, is resigning effective June 10, 2016 to pursue other opportunities. Current board member, Joseph W. Ramelli, will assume the roles of chairman of the board and acting chief executive officer. The board of directors is currently conducting a search for a new CEO. "The Board thanks Mr. French for his efforts and leadership of Marina, including the transition of the company from an oligonucleotide therapeutics company to a late-stage therapeutics company, with the pending completion of our proposed agreement with Turing Pharmaceuticals for its late-stage intranasal ketamine program. We wish him well in his future endeavors," said Mr. Ramelli. "The Board has already begun a search for a new Chief Executive Officer with the expertise and experience necessary to fully execute on the opportunity provided by the ketamine program." About Marina Biotech, Inc.

Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. In addition to these companies, we have also licensed the delivery technology to an undisclosed company developing a gene editing approach to the treatment of human diseases. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com. Recently, Marina announced an agreement with Turing Pharmaceuticals AG under which Marina intends to acquire Turing's intranasal ketamine program. The program has been advanced worldwide with plans for U.S. and international clinical trial sites. The work thus far has predominately been directed at suicidality in post-traumatic stress disorder; a patient population with few, if any, therapeutic options. We believe the early clinical successes of this program combined with broadening acceptance of ketamine as a treatment for neurological and psychiatric diseases, presents a unique opportunity to rapidly move this compound into the U.S. market as early as 2019. In addition, there is some earlier work by academic centers suggesting that intranasal ketamine might be efficacious in patients suffering from certain rare diseases. In addition, the Company will also continue to seek alternatives for its nucleic acid therapeutics assets in order to maximize shareholder value. These alternatives could include the licensing and/or sale of individual nucleic acid chemistry and delivery technologies as well as the sale of the entire drug discovery platform. Marina Biotech Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to consummate the proposed asset acquisition transaction with Turing; (ii) the ability of Marina Biotech to obtain immediate additional funding; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.


For Marina inquires:

Joesph Ramelli

Chairman, Acting CEO

Marina Biotech, Inc.

(805) 262 7621





Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 1.07
MRNA's Price-to-Owner-Earnings is ranked higher than
98% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. MRNA: 1.07 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRNA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.31  Med: 0.66 Max: 9.7
Current: 1.07
0.31
9.7
PB Ratio 8.86
MRNA's PB Ratio is ranked lower than
69% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. MRNA: 8.86 )
Ranked among companies with meaningful PB Ratio only.
MRNA' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 2.88 Max: 387.5
Current: 8.86
0.45
387.5
Current Ratio 0.15
MRNA's Current Ratio is ranked lower than
99% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. MRNA: 0.15 )
Ranked among companies with meaningful Current Ratio only.
MRNA' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.06 Max: 21.21
Current: 0.15
0.03
21.21
Quick Ratio 0.15
MRNA's Quick Ratio is ranked lower than
99% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MRNA: 0.15 )
Ranked among companies with meaningful Quick Ratio only.
MRNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.02 Max: 21.07
Current: 0.15
0.03
21.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -74.30
MRNA's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. MRNA: -74.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -155.1  Med: -22.95 Max: -2.1
Current: -74.3
-155.1
-2.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -8.63
MRNA's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. MRNA: -8.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.63  Med: 53.3 Max: 165.3
Current: -8.63
-8.63
165.3

More Statistics

EPS (TTM) $ -0.17
Beta3.26
Short Percentage of Float8.22%
52-Week Range $0.08 - 0.48
Shares Outstanding (Mil)97.17
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael F Jun 02 2016 
Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals May 03 2016 
Marina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets May 03 2016 
Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology Mar 16 2016 
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech Mar 15 2016 
Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology Feb 18 2016 
Marina Biotech to Explore Strategic Alternatives Feb 17 2016 
Marina Biotech and Hongene Biotechnology Announce License Agreement Sep 28 2015 
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing Aug 06 2015 
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies Apr 23 2015 

More From Other Websites
Marina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2 Apr 27 2017
Marina Biotech Provides Business Update Apr 05 2017
Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer... Apr 03 2017
Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research... Mar 29 2017
Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual... Mar 24 2017
Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at... Mar 13 2017
Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on... Mar 02 2017
Marina Biotech to Participate in the 29th Annual ROTH Conference Mar 01 2017
Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel Feb 28 2017
Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer Feb 21 2017
Marina Biotech Announces Key Additions to its Executive Management Team Feb 14 2017
Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share Feb 10 2017
Marina Biotech Announces a License Agreement to SMARTICLES Feb 07 2017
Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing Jan 03 2017
Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase Dec 27 2016
Philippe P. Calais to Join Marina Biotech's Board of Directors Dec 14 2016
Marina Biotech to Present at the 9th Annual LD Micro Main Event Nov 25 2016
Marina Biotech, Inc. :MRNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 Nov 23 2016
Marina Biotech Announces Merger with IthenaPharma Nov 16 2016
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael... Jun 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)